Botensilimab,balstilimab
agenus
[]
the most promising early phase clinical trial data i have seen online from #gi23 is the actla-4 / apd-1 (colloquially bot/bol combo) in microsatellite stable #colorectalcancer, with 23% orr, durable responses. substantial iraes, as would be expected. nonetheless mss!
Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer. May or may not be notable.